Shares of pharmaceutical company iBio Inc (IBIO) are down more than 8% in pre-market trading Tuesday after an article by the TheStreet’s Adam Feuerstein argued that the name’s current valuation will be hard to maintain “even under the best Ebola stockpiling scenario”. Feuerstein notes in his piece that Ebola related stocks fell Monday after the quarantines for most people who came into contact with U.S. Ebola victim Thomas Eric Duncan ended.
IBIO shares recently lost $0.17 to $2.01. The stock is up more than 522.86% year-over-year and has gained roughly 541.18% year-to-date. In the past 52 weeks, shares of Newark, Delaware-based biotechnology company have traded between a low of $0.24 and a high of $3.48.
iBio, Inc. closed Monday at $2.18. The firm has a total market cap of $147.06M.
Shares of Neonode, Inc. (NEON) climbed over 29% Tuesday after the company announced the signing of a technology development agreement with a leading tier-one printer OEM. Neonode, which has already signed license agreements with printer OEM´s controlling more than 40% of the market, said it believes “the newly signed agreement will solidify [its] position as the preferred touch technology and grow the accessible market share within printer market segment.”
Neonode, Inc., currently valued at $82.93M, has a median Wall Street price target of $7.00 with a high target of $10.00. In the past 52 weeks, shares of Santa Clara, California-based optical-touch technology company have traded between a low of $1.72 and a high of $7.80 with the 50-day MA and 200-day MA located at $2.37 and $3.42 levels, respectively. Additionally, shares of NEON trade at a P/E ratio of (0.20) and have a Relative Strength Index (RSI) and MACD indicator of 41.95 and -0.04, respectively.
NEON currently prints a one year loss of about 66.94% and a year-to-date loss of around 67.56%.
Synergy Pharmaceuticals, Inc. (SGYP) are up nearly 8% to $2.95 in early trade in response to a press release from the company that said its Phase 2b study for Plecanatide in patients with irritable bowel syndrome with constipation was positive. The company plans to initiate phase 3 IBS-C clinical development program in the fourth quarter of this year.
In the past 52 weeks, shares of the $259.74M New York-based biopharmaceutical market cap company have traded between a low of $2.45 and a high of $6.70 and are now at $2.95. Shares are down 37.59% year-over-year and 50.63% year-to-date.
Rhino Resource Partners LP (RNO) shares are getting crushed in pre-market trading on Tuesday, down 51%. The company announced Q3 distribution of $0.05 per unit, lower from previous quarter distribution of $0.445 per unit. Rhino said it is reducing its cost cutting efforts, including reducing overhead to reflect market realities and the company’s smaller size.
This distribution will be paid on November 14, 2014 to all common unitholders of record as of the close of business on October 30, 2014 and no distribution will be paid on the subordinated units.
RNO shares recently lost $6.04 to $5.85. In the past 52 weeks, shares of Lexington, Kentuck-based company have traded between a low of $9.81 and a high of $14.65. Shares are down 0.17% year-over-year ; up 8.49% year-to-date.
Petroleo Brasileiro Petrobras (PBR) shares are falling sharply, down nearly 10% to $12.73, after short guru Jim Chanos described in a Bloomberg interview the Brazilian state-controlled oil company as a “scheme” and recommended betting against it.
PBR is down 1.31 to $12.69 in pre-market trading today. On valuation-measures, shares of Petr have a trailing-12 and forward P/E of 11.27 and 7.22, respectively. P/E to growth ratio is 0.60, while t-12 profit margin is 6.21%. EPS registers at $1.24. The company has a market cap of $91.31B and a median Wall Street price target of $20.00 with a high target of $23.00.
On trading-measure, PBR has a beta of 2.30 and a short float of 0.85%. In the past 52 weeks, shares of oil and gas company have traded between a low of $10.20 and a high of $20.94 with the 50-day MA and 200-day MA located at $16.48 and $15.68 levels, respectively.
PBR currently prints a one year loss of about 6.85% and a year-to-date return of around 5.03%.